N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src |
| |
Authors: | Altmann Eva Widler Leo Missbach Martin |
| |
Affiliation: | Novartis Pharma AG, Therapeutic Area Arthritis and Bone Metabolism, Basel, CH-4002, Switzerland. |
| |
Abstract: | 5-Aryl-pyrrolo[2,3-d]pyrimidines incorporating different N(7)-substituents have been prepared and evaluated for their inhibitory potency towards the tyrosine kinase c-Src. Optimization of these compounds resulted in highly potent c-Src inhibitors, some (e.g. 4g, 6g, 7h, 8l) with excellent specificity towards other receptor and nonreceptor tyrosine kinases. In addition compounds 4g, 5b and 5c are characterized by a good pharmacokinetic profile. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|